Alto Neuroscience Inc
Research Alto Neuroscience Inc (ANRO) on Bullrun: market cap USD 1.27B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerANRO
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.27B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 74.31M
- Free cash flow-USD 27.65M
Valuation Snapshot
latest market cap is USD 1.27B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 63.24M | -USD 51.79M | n/a | -2.19 | USD 176.48M | USD 16.76M | USD 151.14M |
| FY2024 | USD 0 | -USD 61.43M | -USD 49.50M | n/a | -2.5 | USD 168.23M | USD 10.25M | USD 151.46M |
| FY2023 | n/a | -USD 36.31M | -USD 33.92M | n/a | -9.73 | USD 82.55M | USD 9.86M | -USD 71.67M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.27B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 568.24M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 114.15M | n/a | n/a | n/a |
About Alto Neuroscience Inc
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Alto Neuroscience Inc's market cap?
Alto Neuroscience Inc's market capitalization is USD 1.27B.
What does Alto Neuroscience Inc do?
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD).